Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland (CASCADE)
Sponsor: Kantonal Hospital Lucerne
This observational or N/A phase trial investigates Hereditary Breast and Ovarian Cancer and Lynch Syndrome and is currently actively recruiting participants. Kantonal Hospital Lucerne leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Mar 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
-
Jun 2022 — Jan 2024 [monthly]
Recruiting
▶ Show 6 earlier versions
-
May 2021 — Jun 2022 [monthly]
Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
Sep 2019 — Jan 2021 [monthly]
Recruiting
-
Jun 2018 — Sep 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kantonal Hospital Lucerne
- Kantonal Spital Solothurn, Olten
- Kantonal Spital Wallis, Sion
- University of Basel
For direct contact, visit the study record on ClinicalTrials.gov .